A novel hierarchical prognostic model of AML solely based on molecular mutations

Blood

Volumn 120, Issue 15, 2012, Pages 2963-2972

  Grossmann, Vera ^a   Schnittger, Susanne ^a   Kohlmann, Alexander ^a   Eder, Christiane ^a   Roller, Andreas ^a   Dicker, Frank ^a   Schmid, Christoph ^b   Wendtner, Clemens Martin ^c,d   Staib, Peter ^e   Serve, Hubert ^f   Kreuzer, Karl Anton ^d   Kern, Wolfgang ^a   Haferlach, Torsten ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c Klinikum Schwabing   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e ST ANTONIUS HOSPITAL ESCHWEILER   (Germany)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; NUCLEOPHOSMIN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

EID: 84867806184     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-419622     Document Type: Article

References (56)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
2. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood. 2001;98(5):1312-1320.
3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
4. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112(1):118-126. (Pubitemid 32151159)
5. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266. (Pubitemid 40110814)
6. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol. 2011; 29(10):1364-1372.
7. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
8. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66. (Pubitemid 35177429)
9. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-3739. (Pubitemid 41739006)
10. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348-2357.
11. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97(3):388-392.
12. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood. 2011;118(26):6920-6929.
13. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469-2475.
14. Delhommeau F, Dupont S, Della V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
15. Grossmann V, Tiacci E, Holmes AB, et al. Wholeexome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118(23):6153-6163.
16. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
17. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
18. Do&diehner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia-Net. Blood. 2010;115(3):453-474.
19. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009:385-395.
20. Alpermann T, Kern W, Schnittger S, Haferlach C, Haferlach T. Evaluation of the new genetic risk classification of the European LeukemiaNet recommendations in 1,110 patients with de novo AML and proposal of a refined version [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;118(21):Abstract 413.
21. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
22. Kohlmann A, Klein HU, Weissmann S, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25(12):1840-1848.
23. Haferlach C, Dicker F, Herholz H, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539-1541.
24. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121.
25. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12):4116-4124. (Pubitemid 29279253)
26. Schaich M, Rollig C, Soucek S, et al. Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011;29(19):2696-2702.
27. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53-59. (Pubitemid 34105599)
28. Schoch C, Haferlach T, Bursch S, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer. 2002;35(1):20-29. (Pubitemid 34847865)
29. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5):796-804. (Pubitemid 30235055)
30. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220-2231.
31. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110(4):1308-1316. (Pubitemid 47281430)
32. Schnittger S, Bacher U, Eder C, et al. A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. Exp Hematol. 2011;39(1):87-94.
33. Schnittger S, Eder C, Alpermann T, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an extremely poor outcome [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 416.
34. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557-560.
35. Grossmann V, Schnittger S, Schindela S, et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn. 2011;13(2):129-136.
36. Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486-5496.
37. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26(5):934-942.
38. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
39. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079- 1089.
40. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood. 2011;117(9):2577-2584.
41. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29(19):2709-2716.
42. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198-205.
43. Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol. 2004;112(1-2):68-78. (Pubitemid 38716251)
44. Schnittger S, Dicker F, Sundermann J, et al. Applicability of DHPLC for low sensitive residual disease detection in RUNX1 and CEBPA mutated AML [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(111):Abstract 3067.
45. Gaidzik VI, Schlenk R, Paschka P, et al. DNMT3A mutations predict for inferior outcome in NPM1- wildtype and molecular unfavorable cytogenetically-normal acute myeloid leukemia: a study of the German-Austrian AMLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 415.
46. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122-2126.
47. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010;116(4):614-616.
48. Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML Study Group. J Clin Oncol. 2012;30(12):1350-1357.
49. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2011;29(10):1373-1381.
50. Paschka P, Schlenk RF, Herzig J, et al. ASXL1 mutations predict for resistance to chemotherapy and inferior outcome in younger adult patients with acute myeloid leukemia (AML): a study of the German-Austrian AMLSG [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 412.
51. Wouters BJ, Lowenberg B, Erpelinck- Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088-3091.
52. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37(3):237-251. (Pubitemid 36667562)
53. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20(15):3254-3261. (Pubitemid 34831523)
54. Godley LA. Profiles in leukemia. N Engl J Med. 2012;366(12):1152-1153.
55. Kohlmann A, Grossmann V, Harbich S, et al. Monitoring of minimal residual disease using next-generation deep-sequencing in 460 acute myeloid leukemia cases identifies RUNX1 mutated patients with resistant disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 747.
56. Thol F, Kolking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012;51(7):689-695.